Latest Insider Transactions at Verona Pharma PLC (VRNA)
This section provides a real-time view of insider transactions for Verona Pharma PLC (VRNA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Verona Pharma plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Verona Pharma plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 08
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
90,320
-0.72%
|
$993,520
$11.44 P/Share
|
|
Jul 08
2025
|
David Zaccardelli President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
90,320
-0.67%
|
$993,520
$11.44 P/Share
|
|
Jul 08
2025
|
Andrew Fisher General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
39,464
-8.85%
|
$434,104
$11.44 P/Share
|
|
Jul 08
2025
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37,616
-1.43%
|
$413,776
$11.44 P/Share
|
|
Jul 07
2025
|
Mark W Hahn Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
229,512
+1.8%
|
-
|
|
Jul 07
2025
|
David Zaccardelli President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
229,512
+1.68%
|
-
|
|
Jul 07
2025
|
Andrew Fisher General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
86,064
+16.17%
|
-
|
|
Jul 07
2025
|
Kathleen A. Rickard Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
86,064
+3.17%
|
-
|
|
Jun 16
2025
|
Andrew Fisher General Counsel |
SELL
Open market or private sale
|
Direct |
80,000
-18.18%
|
$880,000
$11.53 P/Share
|
|
Jun 16
2025
|
Andrew Fisher General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
80,000
+15.38%
|
$160,000
$2.01 P/Share
|
|
Jun 11
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
400,000
-2.94%
|
$4,400,000
$11.4 P/Share
|
|
Jun 11
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
400,000
-3.15%
|
$4,400,000
$11.4 P/Share
|
|
May 29
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
208,696
-1.51%
|
$1,878,264
$9.33 P/Share
|
|
May 29
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
204,864
-1.59%
|
$1,843,776
$9.33 P/Share
|
|
May 28
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
157,704
-1.13%
|
$1,419,336
$9.3 P/Share
|
|
May 28
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
162,704
-1.25%
|
$1,464,336
$9.3 P/Share
|
|
May 27
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
33,600
-0.24%
|
$302,400
$9.53 P/Share
|
|
May 27
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
32,432
-0.25%
|
$291,888
$9.53 P/Share
|
|
May 20
2025
|
Vikas Sinha Director |
SELL
Open market or private sale
|
Direct |
160,000
-68.25%
|
$1,440,000
$9.39 P/Share
|
|
May 20
2025
|
Vikas Sinha Director |
BUY
Exercise of conversion of derivative security
|
Direct |
160,000
+40.56%
|
$0
$0.5 P/Share
|
|
May 15
2025
|
Andrew Fisher General Counsel |
SELL
Open market or private sale
|
Direct |
80,000
-18.18%
|
$640,000
$8.57 P/Share
|
|
May 15
2025
|
Andrew Fisher General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
80,000
+15.38%
|
$160,000
$2.11 P/Share
|
|
May 14
2025
|
Christina Ackermann Director |
SELL
Open market or private sale
|
Direct |
40,000
-48.85%
|
$320,000
$8.44 P/Share
|
|
May 14
2025
|
Christina Ackermann Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+32.82%
|
$40,000
$1.93 P/Share
|
|
May 06
2025
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
114,984
-4.32%
|
$919,872
$8.82 P/Share
|
|
May 02
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
400,000
-2.78%
|
$3,600,000
$9.09 P/Share
|
|
May 02
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
400,000
-2.97%
|
$3,600,000
$9.09 P/Share
|
|
May 01
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
187,008
-0.65%
|
$1,496,064
$8.95 P/Share
|
|
May 01
2025
|
David Zaccardelli President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
200,000
+1.36%
|
-
|
|
May 01
2025
|
David R Ebsworth Director |
BUY
Exercise of conversion of derivative security
|
Direct |
140,000
+8.66%
|
$140,000
$1.93 P/Share
|
|
May 01
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
187,008
-0.69%
|
$1,496,064
$8.95 P/Share
|
|
May 01
2025
|
Mark W Hahn Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200,000
+1.45%
|
-
|
|
May 01
2025
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
49,200
-0.92%
|
$393,600
$8.95 P/Share
|
|
May 01
2025
|
Kathleen A. Rickard Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+1.83%
|
-
|
|
Apr 29
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
90,360
-0.67%
|
$722,880
$8.98 P/Share
|
|
Apr 29
2025
|
Mark W Hahn Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
229,512
+1.66%
|
-
|
|
Apr 29
2025
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
34,384
-1.28%
|
$275,072
$8.98 P/Share
|
|
Apr 29
2025
|
Kathleen A. Rickard Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
86,064
+3.09%
|
-
|
|
Apr 29
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
90,360
-0.62%
|
$722,880
$8.98 P/Share
|
|
Apr 29
2025
|
David Zaccardelli President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
229,512
+1.56%
|
-
|
|
Apr 29
2025
|
Andrew Fisher General Counsel |
SELL
Open market or private sale
|
Direct |
26,072
-6.75%
|
$208,576
$8.98 P/Share
|
|
Apr 29
2025
|
Andrew Fisher General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
86,064
+18.23%
|
-
|
|
Apr 29
2025
|
Vikas Sinha Director |
SELL
Open market or private sale
|
Direct |
20,000
-11.53%
|
$160,000
$8.92 P/Share
|
|
Apr 29
2025
|
Vikas Sinha Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+10.13%
|
$20,000
$1.1 P/Share
|
|
Mar 19
2025
|
Andrew Fisher General Counsel |
BUY
Bona fide gift
|
Direct |
1
+0.0%
|
-
|
|
Mar 12
2025
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
79,264
-2.95%
|
$634,112
$8.35 P/Share
|
|
Feb 26
2025
|
David R Ebsworth Director |
SELL
Bona fide gift
|
Direct |
64,000
-4.57%
|
-
|
|
Feb 26
2025
|
David R Ebsworth Director |
BUY
Exercise of conversion of derivative security
|
Direct |
460,000
+8.45%
|
$460,000
$1.47 P/Share
|
|
Feb 03
2025
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
33,240
-1.22%
|
$232,680
$7.16 P/Share
|
|
Feb 03
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
166,888
-1.24%
|
$1,168,216
$7.16 P/Share
|